140 related articles for article (PubMed ID: 28471569)
1. Concomitant Treatment with Ibrutinib and Amiodarone Causing Reversible Heart Failure Syndrome.
Wasserstrum Y; Raanani P; Kornowski R; Iakobishvili Z
Isr Med Assoc J; 2016 Jul; 18(7):433-434. PubMed ID: 28471569
[No Abstract] [Full Text] [Related]
2. Ibrutinib-related atrial fibrillation: Therapeutic challenges.
Kapelios CJ; Bonou MS; Diamantopoulos P; Angelopoulou MK; Masoura C; Barbetseas J; Viniou NA
J Oncol Pharm Pract; 2019 Jul; 25(5):1258-1260. PubMed ID: 30012045
[TBL] [Abstract][Full Text] [Related]
3. Atrial fibrillation associated with ibrutinib in Waldenström macroglobulinemia.
Gustine JN; Meid K; Dubeau TE; Treon SP; Castillo JJ
Am J Hematol; 2016 Jun; 91(6):E312-3. PubMed ID: 26994323
[No Abstract] [Full Text] [Related]
4. Adverse event potentially due to an interaction between ibrutinib and verapamil: a case report.
Lambert Kuhn E; Levêque D; Lioure B; Gourieux B; Bilbault P
J Clin Pharm Ther; 2016 Feb; 41(1):104-5. PubMed ID: 26813987
[TBL] [Abstract][Full Text] [Related]
5. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib-Associated Atrial Fibrillation.
Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
[TBL] [Abstract][Full Text] [Related]
7. Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation.
Vrontikis A; Carey J; Gilreath JA; Halwani A; Stephens DM; Sweetenham JW
Oncology (Williston Park); 2016 Nov; 30(11):970-4, 980-1, C3. PubMed ID: 27848243
[No Abstract] [Full Text] [Related]
8. Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Tuomi JM; Xenocostas A; Jones DL
Can J Cardiol; 2018 Mar; 34(3):337-341. PubMed ID: 29475534
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
Lentz R; Feinglass J; Ma S; Akhter N
Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
[TBL] [Abstract][Full Text] [Related]
10. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Boriani G; Corradini P; Cuneo A; Falanga A; Foà R; Gaidano G; Ghia PP; Martelli M; Marasca R; Massaia M; Mauro FR; Minotti G; Molica S; Montillo M; Pinto A; Tedeschi A; Vitolo U; Zinzani PL
Hematol Oncol; 2018 Oct; 36(4):624-632. PubMed ID: 29512173
[TBL] [Abstract][Full Text] [Related]
11. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
12. [Ibrutinib-associated atrial fibrillation : A therapeutic challenge].
Schmitt P; Demoulin R; Poyet R; Capilla E; Rohel G; Pons F; Jégo C; Sidibe S; Prevautel T; Druelle A; Brocq FX; Cellarier GR
Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):321-324. PubMed ID: 36115721
[TBL] [Abstract][Full Text] [Related]
13. Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib.
Chai KL; Rowan G; Seymour JF; Burbury K; Carney D; Tam CS
Leuk Lymphoma; 2017 Dec; 58(12):2811-2814. PubMed ID: 28504030
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib-Associated Reversible Cardiomyopathy.
Liang SH; Chiu CF; Bai LY
J Oncol Pract; 2019 Dec; 15(12):671-673. PubMed ID: 31618089
[No Abstract] [Full Text] [Related]
15. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib-related atrial fibrillation: A single center Australian experience.
Ezad S; Khan AA; Cheema H; Ashraf A; Ngo DTM; Sverdlov AL; Collins NJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e187-e190. PubMed ID: 31250562
[TBL] [Abstract][Full Text] [Related]
17. Paroxysmal atrial fibrillation precipitated by amiodarone-induced thyrotoxicosis five months after cessation of therapy.
Schreiber DH; DeFreest MS
J Emerg Med; 2006 Jul; 31(1):61-4. PubMed ID: 16798157
[TBL] [Abstract][Full Text] [Related]
18. Acute Decompensated Heart Failure After Initiation of Amiodarone in a Patient With Anderson-Fabry Disease.
Fine NM; Wang Y; Khan A
Can J Cardiol; 2019 Jan; 35(1):104.e5-104.e7. PubMed ID: 30595173
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
20. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.
Hampel PJ; Call TG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Rabe KG; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
Am J Hematol; 2020 Mar; 95(3):E57-E60. PubMed ID: 31788844
[No Abstract] [Full Text] [Related]
[Next] [New Search]
